Dr. Mercè Boada has been appointed member of InRAD’s Scientific Leadership Group, reinforcing its role as an international reference in Alzheimer’s research and treatment.

Mercè Boada, member of the Scientific Leadership Group of InRAD

Dr. Mercè Boada, medical director and co-founder of Ace, has recently been appointed member of the Scientific Leadership Group (SLG) of the International Registry for Alzheimer's Disease and Other Dementias (InRAD). This appointment reinforces her role as an international reference in the research and treatment of Alzheimer's disease and other neurodegenerative diseases.

InRAD: A global platform for Alzheimer's research

The international InRAD registry aims to improve Alzheimer's care and clinical outcomes through real-time data collection and analysis. Its mission is to foster international collaboration and create a unified platform to drive research and advance understanding of these pathologies.

As a member of the SLG, Dr. Boada will contribute to define InRAD's scientific agenda, bringing her experience and vision to the development of innovative research in neuroscience.

Commitment to research and collaboration

Dr. Boada's participation in this committee underlines the importance of establishing global connections to improve care for people affected by Alzheimer's disease. In addition, Dr. Boada will actively participate in the upcoming InRAD inaugural meetings, most notably the face-to-face meeting on 2 April 2025, in the framework of the AD/PD congress in Vienna.

According to Mercè Boada, ‘being part of InRAD's Scientific Leadership Group is a great opportunity to contribute to a global platform that not only collects data in real time, but also fosters collaboration between international institutions’. She adds that ‘these types of initiatives are essential to transform knowledge into tangible solutions that improve the quality of life of people with Alzheimer's disease and their families’.

At Ace, we celebrate this new milestone in its trajectory, which reflects our commitment to scientific excellence and international impact in Alzheimer's research.

Ace:
News